Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abivax    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report  
Delayed Quote. Delayed Euronext Paris - 04/18 11:09:34 am
10.14 EUR   +1.40%
03/11ABIVAX SA : annual earnings release
2018ABIVAX : Pr_abivax_ecco_20122018
PU
2018ABIVAX : Half-year results
CO
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
10.14(c) 10.3(c) 10.2(c) 10(c) 10.14(c) Last
10 909 20 792 4 558 7 685 8 334 Volume
+0.60% +1.58% -0.97% -1.96% +1.40% Change
More quotes
Financials (EUR)
Sales 2019 37,5 M
EBIT 2019 15,1 M
Net income 2019 -14,0 M
Finance 2019 2,00 M
Yield 2019 -
Sales 2020 38,0 M
EBIT 2020 8,01 M
Net income 2020 -14,0 M
Debt 2020 3,00 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 2,62x
EV / Sales2020 2,72x
Capitalization 100 M
More Financials
Company
ABIVAX is a biotechnology company specializing in immune system targeting for viral diseases. The group operates three technological platforms: ?antiviral', ?immune stimulation' and ?polyclonal antibody' platform. The most advanced product, ABX464, is currently in Phase II clinical trial to assess... 
Sector
Biotechnology & Medical Research
Calendar
05/21 | 02:00pmPresentation
More about the company
Latest news on ABIVAX
03/11ABIVAX SA : annual earnings release
2018ABIVAX : Pr_abivax_ecco_20122018
PU
2018ABIVAX : Half-year results
CO
2018ABIVAX SA : half-yearly earnings release
2018ABIVAX : reports impressive results in clinical phase 2a trial of ABX464 as an o..
AQ
2018ABIVAX : Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 ..
PU
2018ABIVAX : Study indicates potential breakthrough HIV drug
AQ
2018ABIVAX : announces the publication of its 2018 Registration Document
PU
2018ABIVAX SA : annual earnings release
2018ABIVAX : to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcera..
PU
More news
Analyst Recommendations on ABIVAX
More recommendations
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ABIVAX
Duration : Period :
Abivax Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 18,9 €
Spread / Average Target 86%
EPS Revisions
Managers
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Philippe Pouletty Chairman
Didier Blondel Chief Financial Officer & Secretary
Didier Scherrer Vice President-Research & Development
Jean-Marc Steens Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX-14.36%113
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596